Influences of dapagliflozin on blood pressure variability and left ventricular mass index in patients with type 2 diabetes mellitus and hypertension
10.12173/j.issn.1008-049X.202311124
- VernacularTitle:达格列净对2型糖尿病合并高血压病患者血压变异性和左心室质量指数作用的研究
- Author:
Sa-Sa LI
1
;
Bei-Bei YE
;
Xin LIU
;
Xia-Ling ZHU
Author Information
1. 丽水市中心医院心血管内科(浙江丽水 323000)
- Keywords:
Dapagliflozin;
Type 2 diabetes mellitus;
Hypertension;
Blood pressure variability;
Left ventricular mass index
- From:
China Pharmacist
2023;26(12):413-419
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of dapagliflozin on blood pressure variability(BPV)and left ventricular mass index(LVMI)in patients with type 2 diabetes mellitus(T2DM)and hypertension.Methods Patients with T2DM complicated with hypertension admitted to Lishui Central Hospital from August 2021 to August 2022 were selected as the study subjects,and were treated with conventional treatment(control group)and dapagliflozin treatment(test group),respectively.The changes of BPV index,LVMI,blood glucose level and the incidence of adverse reactions were compared between the two groups.Results A total of 94 patients with T2DM and hypertension were included in the study,including 47 patients in the test group and 47 in the control group.The 24-hour diastolic blood pressure(DBP),24-hour systolic blood pressure(SBP),24-hour systolic standard deviation(SSD),24-hour diastolic standard deviation(DSD),fasting blood glucose(FBG),2-hour blood glucose(PG),glycated hemoglobin glycosylated hemoglobin(HbA1c),body mass index(BMI)and LVMI of the patients with T2DM and hypertension were significantly decreased in the two groups(P<0.05),and the 24-hour SBP,24-hour DBP,24-hour SSD,24-hour DSD,FPG,2-hour PG,HbA1c,BMI and LVMI in the test group were lower than those in the control group(P<0.05).The total incidence of adverse reactions between the test group and the control group was 10.64% and 4.26% ,respectively,and the difference was not statistically significant(P>0.05).Conclusion Dapagliflozin can reduce LVMI and improve BPV and blood glucose levels in patients with T2DM and hypertension,and has a good safety profile.
